Lupus News Today Home | Lupus News Today
2024年11月25日 · Cell therapy SC291 gets FDA fast track designation for SLE. The U.S. Food and Drug Administration (FDA) has granted fast track designation to experimental cell therapy SC291 as a potential treatment for hard-to-manage systemic lupus erythematosus (SLE).
News Archives - Lupus News Today
Cell therapy SC291 gets FDA fast track designation for SLE. The U.S. Food and Drug Administration (FDA) has granted fast track designation to experimental cell therapy SC291 as a potential treatment for hard-to-manage systemic lupus erythematosus (SLE).
Lupkinis plus MMF most effective as treatment for lupus nephritis
2024年1月8日 · The treatment was also associated with the highest risk of infections and serious infections, indicating a lower safety profile than other immunosuppressive therapies, such as tacrolimus, which showed a high efficacy, but had the lowest risk of infections compared with other immunosuppressants, making it a more favorable treatment option regarding safety.
About Us - Lupus News Today
Lupus News Today is a digital platform intended to provide the lupus community with the most recent news and information, as well as first-hand community perspectives from our patient and caregiver columnists.. All articles on Lupus News Today are original content produced by in-house writers and editors. Occasionally, we seek the opinion of outside experts for interviews and Q&As.
FDA updates Lupkynis label to include long-term efficacy data
2024年5月6日 · The data came from AURORA 2 (NCT03597464), a two-year extension to the one-year Phase 3 AURORA 1 trial (NCT03021499) that looked at how safe Lupkynis is and how well it works in adults with lupus nephritis when given on top of mycophenolate mofetil (MMF) and low-dose corticosteroids.. After three years, more patients on Lupkynis achieved a sustained complete renal response — meaning they had ...
Lupus overview - Lupus News Today
2023年2月9日 · What are the causes of lupus? An autoimmune disorder, lupus is caused by the immune system attacking healthy cells as if they are an infectious threat. The symptoms that develop are largely dependent on which body part(s) are most affected. As a characteristic part of the autoimmune attack in lupus, immune cells make proteins called antinuclear autoantibodies (ANAs), which play a key role in ...
Phase 2b Lupus Trial Shows Positive Results for Neovacs' IFN-a …
2018年7月11日 · Neovacs developed its immunotherapy, or vaccine, candidate to block all 13 subtypes of IFN-alpha, taking advantage of a proprietary technology called Kinoid technology, which stimulates a patient’s immune system to produce its own antibodies against IFN-alpha.. The randomized, double-blind, placebo-controlled Phase 2b trial (NCT02665364) is evaluating IFN-alpha Kinoid for the treatment of ...
MyLupus mobile phone app aims to help patients in care decisions
2024年1月25日 · Goal of new mobile phone app is educating lupus patients. The patient-focused mobile phone app was developed out of a multicenter, observational study dubbed IDEAL (NCT03735238), sponsored by UAB.The $2.2 million Patient-Centered Outcomes Research Institute-funded study, which is still recruiting participants, involves testing three shared decision-making strategies in at least 500 adults with ...
Long-term safety of Lupkynis for SLE confirmed in AURORA trial
2023年4月10日 · New top-line data show participants in the Lupkynis treatment arm of the now completed Phase 3 AURORA trial (NCT03021499) had similar kidney biopsy (histologic) findings as those in the active control arm receiving mycophenolate mofetil, an immunosuppressant sold under the brand name CellCept, and low-dose steroids alone.. These results contrast with the well-known kidney-related side effects ...
Advancing lupus treatments aim of new Lupus ABC consortium
2023年4月3日 · The patient-focused Lupus Accelerating Breakthroughs Consortium (Lupus ABC) will also be made up of other federal agencies, as well as industry representatives, medical societies, scientists, and academic clinical researchers. “Public-private partnerships such as Lupus ABC can play a critical role in addressing gaps in drug development in a collaborative, pre-competitive setting.